b_leftb_right
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Editorial

Moving upwards – the journal of cachexia, sarcopenia and muscle in 2016

Stephan von Haehling*, Nicole Ebner, Stefan D. Anker

Version of Record online: 6 SEP 2016

DOI: 10.1002/jcsm.12142


How to Cite

von Haehling, S., Ebner, N., and Anker, S. D. (2016) Moving upwards – the journal of cachexia, sarcopenia and muscle in 2016. Journal of Cachexia, Sarcopenia and Muscle, 7: 391395. doi: 10.1002/jcsm.12142.

Author Information

Innovative Clinical Trial, Department of Cardiology and Pneumology, University of Göttingen Medical School, Göttingen, Germany

*Correspondence to: Dr Stephan von Haehling, Institute of Innovative Clinical Trials, Department of Cardiology and Pneumology, University of Göttingen Medical School, Robert-Koch-Strasse 40, 37075 Göttingen, Germany. Tel.: +49 551 39 20911; Fax: +49 551 39 20918; Email stephan.von.haehling@web.de


The good news first, the Journal of Cachexia, Sarcopenia and Muscle (JCSM) has not only maintained its impact factor, but it has even increased it again, now reaching 7.883 as has been published by Thomson Scientific a few weeks ago. This places JCSM again as the number 9 ranked journal amongst all journals in ‘Medicine, General and Internal’ (Table 1) and as number 2 ranking publication amongst all nutrition journals, amongst which; however, JCSM is still not offficially listed by Thomson Scientific (Table 2). This new impact factor re-confirms the inaugural impact factors of 7.413 for 2013 and 7.315 for 2014. As before, we would like to sincerely thank all authors, reviewers and editorial board members for their great efforts to produce JCSM at good quality, and we greatly appreciate and value also the interest and support of all those who enjoy reading JCSM and cite the papers published there.

Table 1. Top ten journals in the field ‘Medicine: General & Internal’, adapted from reference 1
 Journal nameImpact factor 2016Items published in 2014 & 2015
1New England journal of medicine59.558701
2Lancet44.002547
3Journal of the American medical association (JAMA)37.684449
4British medical journal19.697519
5Annals of internal medicine16.440325
6JAMA internal medicine14.000332
7PLOS medicine13.585246
8BMC medicine8.005379
9Jounal of cachexia sarcopenia and muscle7.88360
10Journal of internal medicine7.803198
Table 2. Top ten journals in the field ‘Nutrition & Dietetics’, where the journal of cachexia, sarcopenia and muscle is officially not listed
 Journal nameImpact factor 2016

Items published

in 2014 & 2015

1Progress in lipid research11.23863
2Annuals review of nutrition6.78437
3American journal of clinical nutrition6.703671
4Nutrition reviews5.591149
5Critical reviews in food science and nutrition5.492185
6International journal of obesity5.337484
7Proceedings of the nutrition society4.703111
8Journal of nutritional biochemistry4.668398
9Advances in nutrition4.576158
10Clinical nutrition4.487318

This year is special for JCSM for several reasons. One is the publication of an additional (5th) issue in May this year, the other the launch dedicated daughter journals. Indeed, JCSM appears to have sparked more scientific interest in the field of body wasting, cachexia and sarcopenia; and thus, the number of submissions to the main journal remains on the increase. With a 78% rejection rate – knowing that we have to decline publication of many good papers, simply for lack of space – we hope to be able to give some of these a home in our new daughter journals – JCSM Rapid Communications and JCSM Clinical Reports. These journals will be published online only on an open access basis, and we hope that they will help to create a family of journals dedicated to this fascinating field of research into cachexia, sarcopenia and muscle, and that they will help in clinical decision making and in serving as a source of clinical information and case reports as well.

The main journal, JCSM, at the time of this writing this editorial on 18 July 2016, the journal has received 158 submissions in 2016 alone (Figure 1). Last year at this time, we had received 106 submissions .[51] Given these higher numbers of submissions, in 2017, we will move to six issues per year to allow publication of more accepted papers. If all goes well, in 2018, we could then possibly move to publication of eight issues per year.

Figure 1.

Figure 1.

Number of manuscript submissions to the Journal of Cachexia, Sarcopenia and Muscle by year of publication. *Numbers for 2016 are estimated on the number of submissions until 18 July 2016 (Reprinted from [51]).

We are working hard to provide a timely peer review, which is not always easy, as it is difficult at times to find appropriate reviewers. Articles that are available for the longest time are – not surprisingly – those that have been cited most (Table 3). Our ‘facts and numbers’ editorials remain popular (Tables 4 and 5), and we invite our readers to submit their work or to suggest topics for ‘facts and numbers’ editorials that are relevant to our readers.

Table 3. Top twenty of best cited articles since first publication of the journal of cachexia, sarcopenia and muscle
 First authorTitleTypeYearTimes citedReference
1.von HaehlingCachexia as a major underestimated and unmet medical need: facts and numbersEditorial20101812
2.von HaehlingAn overview of sarcopenia: facts and numbers on prevalence and clinical impactEditorial2010943
3.DaltonThe selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trialOriginal Article2011884
4.LenkSkeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise trainingReview2010865
5.MakWasting in chronic kidney diseaseReview2011666
6.FanzaniMolecular and cellular mechanisms of skeletal muscle atrophy: an updateReview2012637
7.ElkinaThe role of myostatin in muscle wasting: an overview.Review2011638
8.CesariBiomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on SarcopeniaOriginal Article2012609
9.LainscakBody mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary diseaseOriginal Article20115510
10.MorleyFrom sarcopenia to frailty: a road less traveledEditorial20145411
11.von HaehlingFrom muscle wasting to sarcopenia and myopenia: update 2012Editorial20125212
12.LainscakThe obesity paradox in chronic disease: facts and numbersEditorial20124413
13.PatelSerum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literatureReview20134314
14.FearonMyopenia-a new universal term for muscle wastingEditorial20114315
15.SakumaSarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle massReview20124216
16.SchefoldIntensive care unit-acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shockReview20104117
17.BusquetsMyostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performanceOriginal Article20123918
18.WakabayashiRehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care managementReview20143719
19.FarkasCachexia as a major public health problem: frequent, costly, and deadlyReview20133720
20.RozentrytThe effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot studyOriginal Article20103521
Table 4. Top twenty of best cited articles published 2014 in the journal of cachexia, sarcopenia and muscle
 First authorTitleTypeYearTimes citedReference
1.MorleyFrom sarcopenia to frailty: a road less traveledEditorial20145411
2.WakabayashiRehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care managementReview20143719
3.von HaehlingPrevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014Editorial20142922
4.MorleyAre we closer to having drugs to treat muscle wasting disease?Editorial20142623
5.AnkerMuscle wasting disease: a proposal for a new disease classificationEditorial20142424
6.EbnerHighlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategiesMeeting Report20142325
7.HeymsfieldAssessing skeletal muscle mass: historical overview and state of the artReview20142126
8.PietraAnamorelin HCI (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profileOriginal Article20142027
9.MorleyPrevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014Editorial20141728
10.FragalaBiomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adultsOriginal Article20141529
11.ToledoFormoterol in the treatment of experimental cancer cachexia: effects on heart functionOriginal Article20141330
12.RheeResistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients?Editorial20141231
13.ArgilesCachexia: a problem of energetic inefficiencyReview20141132
14.PoetschThe anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old ratsOriginal Article20141133
15.HenwoodAssessing sarcopenic prevalence and risk factors in residential aged care: methodology and feasibilityOriginal Article20141034
16.OrmsbeeOsteosarcopenic obesity: the role of bone, muscle, and fat on healthReview20141035
17.AlchinSarcopenia: describing rather than defining a conditionReview2014936
18.MirzaAttenuation of muscle wasting in murine C2C12 myotubes by epigallocatechin-3-gallateOriginal Article2014937
19.KirkmanAnabolic exercise in haemodialysis patients: a randomised controlled pilot studyOriginal Article2014838
20.PalusMuscle wasting: an overview of recent developments in basic researchReview2014839
Table 5. Top ten of the best cited articles published 2015 in the journal of cachexia, sarcopenia and muscle
 First authorTitleTypeYearTimes citedReference
1.ChenGhrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involvedOriginal Article2015740
2.SassoA framework for prescription in exercise-oncology researchEditorial2015641
3.StephensEvaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patientsOriginal Article2015642
4.CalvaniBiomarkers for physical frailty and sarcopenia: state of the science and future developmentsReview2015443
5.EzeokePathophysiology of anorexia in the cancer cachexia syndromReview2015444
6.FearonRequest for regulatory guidance for cancer cachexia intervention trialsEditorial2015445
7MorleyRapid screening for sarcopeniaEditorial2015346
8.BrowenSkeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise trainingReview2015447
9.FaberImproved body weight and performance status and reduced serum PGE(2) levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junctionOriginal Article2015448
10.TrobecInfluence of cancer cachexia on drug liver metabolism and renal elimination in ratsOriginal Article2015449

Finally, we would like to draw your attention to the up-coming Cachexia Conference, to be held on December 10–11, 2016 in Berlin, Germany. The conference now goes annually, and it has been a source of stimulating ideas and exchange between clinicians and researchers in the field of cachexia and wasting. More information can be found at the following link: http://society-scwd.org.

Acknowledgements

The authors certify that they comply with the ethical guidelines for authorship and publishing of the Journal of Cachexia, Sarcopenia and Muscle.[52]

References

1n.d www.webofknowledge.com (accessed 18/07/2016).
2von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 2010;1:15.3von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle 2010;1:129133.4Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2011;2:153161.5Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2010;1:921.6Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K. Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle 2011;2:925.7Fanzani A, Conraads VM, Penna F, Martinet W. Molecular and cellular mechanisms of skeletal muscle atrophy: an updatee. J Cachexia Sarcopenia Muscle 2012;3:16379.8Elkina Y, von Haehling S, Anker SD, Springer J. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle 2011;2:143151.9Cesari M, Fielding RA, Pahor M, Goodpaster B, Hellerstein M, van Kan GA, Anker SD, Rutkove S, Vrijbloed JW, Isaac M, Rolland Y, M'rini C, Aubertin-Leheudre M, Cedarbaum JM, Zamboni M, Sieber CC, Laurent D, Evans WJ, Roubenoff R, Morley JE. Vellas B for the international working group on sarcopenia. Biomarkers of sarcopenia in clinical trials-recommendations from the international working group on sarcopenia. J Cachexia Sarcopenia Muscle 2012;3:18190.10Lainscak M, von Haehling S, Doehner W, Sarc I, Jeric T, Ziherl K, Kosnik M, Anker SD, Suskovic S. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. J Cachexia Sarcopenia Muscle 2011;2:8186.11Morley JE, von Haehling S, Anker SD, Vellas B. From sarcopenia to frailty: a road less traveled. J Cachexia Sarcopenia Muscle 2014;5:58.12von Haehling S, Morley JE, Anker SD. From muscle wasting to sarcopenia and myopenia: update 2012. J Cachexia Sarcopenia Muscle 2012;3:213217.13Lainscak M, von Haehling S, Doehner W, Anker SD. The obesity paradox in chronic disease: facts and numbers. J Cachexia Sarcopenia Muscle 2012;3:14.14Patel SS, Molnar MZ, Tayek JA, Ix JH, Noori N, Benner D, Heymsfield S, Kopple JD, Kovesdy CP, Kalantar-Zadeh K. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle 2013;4:1929.15Fearon K, Evans WJ, Anker SD. Myopenia-a new universal term for muscle wasting. J Cachexia Sarcopenia Muscle 2011;2:13.16Sakuma K, Yamaguchi A. Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. J Cachexia Sarcopenia Muscle 2012;2:7794.17Schefold JC, Bierbrauer J, Weber-Carstens S. Intensive care unit-acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shock. J Cachexia Sarcopenia Muscle 2010;1:147157.18Busquets S, Toledo M, Orpí M, Massa D, Porta M, Capdevila E, Padilla N, Frailis V, López-Soriano FJ, Han HQ, Argilés JM. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle 2012;3:3743.19Wakabayashi H, Sakuma K. Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management. J Cachexia Sarcopenia Muscle 2014;5:269277.20Farkas J, von Haehling S, Kalantar-Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle 2013;4:173178.21Rozentryt P, von Haehling S, Lainscak M, Nowak JU, Kalantar-Zadeh K, Polonski L, Anker SD. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle 2010;1:3542.22von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle 2014;5:261263.23Morley JE, von Haehling S, Anker SD. Are we closer to having drugs to treat muscle wasting disease? J Cachexia Sarcopenia Muscle 2014;5:8387.24Anker SD, Coats AJS, Morley JE, Rosano G, Bernabei R, von Haehling S, Kalantar-Zadeh K. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle 2014;5:13.25Ebner N, Steinbeck L, Doehner W, Anker SD, von Haehling S. Highlights from the 7th cachexia congerence: muscle wasting pathophysiological detection and novel treatment strategies. J Cachexia Sarcopenia Muscle 2014;5:2734.26Heymsfield SB, Adamek M, Gonzalez MC, Jia G, Thomas DM. Assessing skeletal muscle mass: historical overview and state of the art. J Cachexia Sarcopenia Muscle 2014;5:918.27Pietra C, Takeda Y, Tazawa-Ogata N, Minami M, Xia YF, Duus EM, Northrup R. Anamorelin HCI (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle 2014;5:329337.28Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle 2014;5:253259.29Fragala MS, Jajtner AR, Beyer KS, Townsend JR, Emerson NS, Scanlon TC, Oliveira LP, Hoffman JR, Stout JR. Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults. J Cachexia Sarcopenia Muscle 2014;5:139148.30Toledo M, Springer J, Busquets S, Tschirner A, López-Soriano FJ, Anker SD, Argilés JM. Formoterol in the treatment of experimental cancer cachexia: effects on heart function. J Cachexia Sarcopenia Muscle 2014;5:31520.31Rhee CM, Kalantar-Zadeh K. Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients? J Cachexia Sarcopenia Muscle 2014;5:315320.32Argilés JM, Fontes-Oliveira CC, Toledo M, López-Soriano FJ, Busquets S. 34Cachexia: a problem of energetic inefficiency. J Cachexia Sarcopenia Muscle 2014;5:279286.33Pötsch MS, Tschirner A, Palus S, von Haehling S, Doehner W, Beadle J, Coats AJ, Anker SD, Springer J. The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. J Cachexia Sarcopenia Muscle 2014;5:149158.34Henwood TR, Keogh JW, Reid N, Jordan W, Senior HE. Assessing sarcopenic prevalence and risk factors in residential aged care: methodology and feasibility. J Cachexia Sarcopenia Muscle 2014;5:229236.35Ormsbee MJ, Prado CM, Ilich JZ, Purcell S, Siervo M, Folsom A, Panton L. Osteosarcopenic obesity: the role of bone, muscle, and fat on health. J Cachexia Sarcopenia Muscle 2014;5:183192.36Alchin DR. Sarcopenia: describing rather than defining a condition. J Cachexia Sarcopenia Muscle 2014;5:265268.37Mirza KA, Pereira SL, Edens NK, Tisdale MJ. Attenuation of muscle wasting in murine C2C12 myotubes by epigallocatechin-3-gallate. J Cachexia Sarcopenia Muscle 2014;5:339345.38Kirkman DL, Mullins P, Junglee NA, Kumwenda M, Jibani MM, Macdonald JH. Anabolic exercise in haemodialysis patients: a randomised controlled pilot study. J Cachexia Sarcopenia Muscle 2014;5:199207.39Palus S, von Haehling S, Springer J. Muscle wasting: an overview of recent developments in basic research. J Cachexia Sarcopenia Muscle 2014;5:193198.40Chen JA, Splenser A, Guillory B, Luo JH, Mendiratta M, Belinova B, Halder T, Zhang GH, Li YP, Garcia JM. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle 2015;6:132143.41Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for prescription in exercise-oncology research. J Cachexia Sarcopenia Muscle 2015;6:115124.42Stephens NA, Skipworth RJE, Gallagher IJ, Greig CA, Guttridge DC, Ross JA, Fearon KCH. Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients. J Cachexia Sarcopenia Muscle 2015;6:5361.43Calvani R, Marini F, Cesari M, Tosato M, Anker SD, von Haehling S, Miller RR, Bernabei R, Landi F, Marzetti E. Group Author(s): SPRINTT Consortium. Biomarkers for physical frailty and sarcopenia: state of the science and future developments. J Cachexia Sarcopenia Muscle 2015;6:278286.44Ezeoke CC, Morley JE. Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle 2015;6:287302.45Fearon KCH, Argiles JM, Baracos VE, Bernabei R, Coats AJS, Crawford J, Deutz NE, Doehner W, Evans WJ, Ferrucci L, Garcia JM, Gralla RJ, Jatoi A, Kalantar-Zadeh K, Lainscak M, Morley JE, Muscaritoli M, Polkey MI, Rosano G, Rossi-Fanelli F, Schols AM, Strasser F, Vellas B, von Haehling S, Anker SD. Request for regulatory guidance for cancer cachexia intervention trials. J Cachexia Sarcopenia Muscle 2015;6:272274.46Morley JE, Cao L. Rapid screening for sarcopenia. J Cachexia Sarcopenia Muscle 2015;6:312314.47Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2015;6:197207.48Faber J, Uitdehaag MJ, Spaander M, van Steenbergen-Langeveld S, Vos P, Berkhout M, Lamers C, Rumke H, Tilanus H, Siersema P, van Helvoort A, van der Gaast A. Improved body weight and performance status and reduced serum PGE(2) levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. J Cachexia Sarcopenia Muscle 2015;6:3244.49Trobec KC, Kos MK, Trontelj J, Grabnar I, Tschirner A, Palus S, Anker SD, Springer J, Lainscak M. Influence of cancer cachexia on drug liver metabolism and renal elimination in rats. J Cachexia Sarcopenia Muscle 2015;6:4552.50von Haehling S, Anker SD. More colour to the Journal: new style, new publisher, but still cachexia. Sarcopenia and Muscle J Cachexia Sarcopenia Muscle 2015;6:1.51von Haehling S, Anker SD. Moving on up: the journal of cachexia, sarcopenia and muscle. J Cachexia Sarcopenia Muscle 2015;6:1936.52von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015. J Cachexia Sarcopenia Muscle 2015;6:3156.